目的：分析尼可地尔对冠状动脉支架植入术后患者白细胞介素（IL）-10、IL-17和C反应蛋白（CRP）水平及术后再狭窄的影响。方法将本院2013年1月至2014年12月收治的64例行冠状动脉支架植入术患者随机分为治疗组和对照组，每组各32例。两组患者均给予调脂、抗血小板等对症治疗，治疗组患者在上述治疗基础上给予尼可地尔。比较两组患者术后再狭窄发生率，IL-10、IL-17、CRP水平变化及心血管事件发生情况。结果治疗组患者术后3、6、12个月再狭窄发生率均显著低于对照组（P＜0.05）。术后12个月治疗组患者IL-10、IL-17、CRP水平改善显著优于对照组（P＜0.05）。治疗组患者心绞痛、心律失常发生率显著低于对照组（P＜0.05），两组患者传导阻滞、心源性休克发生率及死亡率比较差异均无显著性（P＞0.05）。结论尼可地尔能够改善冠状动脉支架植入术后再狭窄，减轻炎性反应，降低术后冠状动脉再狭窄及不良心血管事件的发生率。%ObjectiveTo analyze the nicorandil on coronary stent implantation in patients with interleukin (IL) -10 and IL-17, C-reaction protein (CRP) levels and postoperative restenosis.MethodFrom January 2013 to December 2014, 64 patients were given coronary stent implantation in our hospital. All cases were randomly divided into treatment group and control group, 32 cases in each group. All patients were treated with lipid-lowering, anti-platelet and other symptomatic treatment, treatment group patients were given nicorandil on the basis of the above. Compared the incidence of restenosis, IL-10, IL-17, CRP levels and the incidence of cardiovascular events.ResultThe incidence of restenosis of treatment group was significantly lower than control group at 3, 6, 12 months after operation (P<0.05). The levels of IL-10, IL-17 and CRP of treatment group improved significantly more than control group 18 months after treatment (P<0.05). The incidence of angina pectoris, arrhythmia occurrence of treatment group was significantly lower than control group (P<0.05). There was no significant difference between two groups of patients in the incidence of conduction block, cardiac shock and the mortality (P>0.05).ConclusionNicorandil can improve coronary stent restenosis, reduce inflammation and reduce the incidence of postoperative restenosis and adverse cardiovascular events.
展开▼
